Monogram Biosciences has a legacy of developing state-of-the-art, highly reproducible, high-throughput assays in a clinical reference laboratory setting. There is increasing demand from companies developing novel HCV agents for assays to monitor susceptibility and resistance to inhibitors of the polymerase (NS5B) and protease (NS3/4A). Monogram is well positioned to apply its expertise to develop genotypic (sequencing) and phenotypic assays for HCV viral resistance to drugs that act on polymerase (NS5B) and protease (NS3) regions of the viral genome.

As is the case for HIV, it is likely that both genotypic and phenotypic assays will be required to provide complementary information and that both assay systems will become essential tools for HCV drug development and possibly for patient management.  Monogram has an established vision and plan for the development of genotypic and phenotypic HCV resistance assays.

Currently, Monogram offers RUO validated NS5B genotype testing services to clients for retrospective research studies, and is establishing partnerships with companies that have active HCV programs for further development of additional prototype assays.

For more information on Monogram assays, services and pricing, please contact us.